Mr. Jeffrey Bacha reports

RAKOVINA THERAPEUTICS ANNOUNCES EXTENSIONS AND EXPANSIONS OF STRATEGIC COLLABORATIONS TO SUPPORT AI RESEARCH

Rakovina Therapeutics Inc. has expanded two research collaborations to align with its recently announced collaboration with the Deep Docking AI (artificial intelligence) drug discovery platform.

On March 27, 2024, the Company announced an agreement granting Rakovina Therapeutics exclusive access to the proprietary Deep Docking AI platform for DNA-damage response targets. Using the Deep Docking AI platform, the Company is analyzing billions of molecular structures to evaluate their potential as targeted cancer drugs.

"These partnerships allow us to capitalize on the Deep Docking AI platform while maintaining high standards of research," said Rakovina Therapeutics Executive Chairman, Jeffrey Bacha. "The most promising lead candidates will be validated using the Company's established R&D infrastructure and advanced to human clinical trials and pharmaceutical partnerships."

To support these drug development efforts, the Company has expanded a collaboration with Pharma Inventor Inc., a British Columbia-based chemistry R&D and analytical services company serving pharmaceutical and biotech industries, as well as research institutes and academic research groups across North America. Pharma Inventor has agreed to provide medicinal chemistry support to rapidly synthesize novel lead drug candidates identified by the Deep Docking AI platform for further validation by the Company. Rakovina Therapeutics will own all rights to novel molecules developed through the collaboration.

The Company has also extended and expanded its collaborative research agreement with the University of British Columbia (UBC). Rakovina Therapeutics' established lead optimization research infrastructure at the University's Vancouver Prostate Center will provide rapid validation of novel drug candidates identified through the Deep Docking AI platform.

According to Rakovina Therapeutics President and Chief Scientific Officer, Dr. Mads Daugaard, "We are expanding these important research collaborations to support the company's recently announced collaboration with the Deep Docking AI platform. This ramp-up will position us to capitalize on the opportunity of this collaboration."

"Over the next 12 to 16 weeks, we intend to screen six to eight billion compounds against our initial DDR target and anticipate synthesizing a short-list of the most promising novel drug candidates for in vitro and in vivo validation through our in-house laboratory infrastructure," he added. Dr. Daugaard is also a professor at UBC.

"Our goal is to advance promising lead candidates toward clinical trials through collaboration with pharmaceutical development partners. With recent announcements of pre-clinical licensing deals in the DNA-damage response arena, we're confident in our ability to generate shareholder value in the near term," said Bacha.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at www.rakovinatherapeutics.com.

About Pharma Inventor Inc.

Pharma Inventor Inc. is a Canadian chemistry research and development and analytical services company located in Vancouver, British Colombia. Pharma Inventor was established in 2013 to provide inventive and high-quality medicinal chemistry solutions in drug discovery research. Pharma Inventor has established a state-of-the-art medicinal chemistry facility relevant to AI-based drug discovery. Its skilled team of international scientists serve the needs of pharmaceutical, biotech, research institutes and academic research groups to expedite their discovery R&D projects with innovative chemistry solutions. Further information may be found at www.pharmainventor.com.

We seek Safe Harbor.